Tandem Diabetes Care (TNDM) furnishes Q3 2025 results release

Tandem Diabetes Care (TNDM) furnished a press release reporting its financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Tandem Diabetes Care (TNDM) furnished a press release reporting its financial results for the quarter ended September 30, 2025. The release is provided as Exhibit 99.1 and incorporated by reference in this report.

The company notes that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liability of the Exchange Act or automatically incorporated into other filings unless specifically referenced.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TNDM announce in its 8-K?

The company furnished a press release reporting financial results for the quarter ended September 30, 2025, as Exhibit 99.1.

Which period do the reported results cover for TNDM?

The quarter ended September 30, 2025.

How is the information in Item 2.02 and Exhibit 99.1 treated?

It is furnished, not filed, and not subject to Section 18 of the Exchange Act.

Is the press release automatically incorporated into other SEC filings?

No. It is not incorporated by reference unless expressly set forth by specific reference.

Where can investors find the detailed results for TNDM?

In Exhibit 99.1 to the report, which contains the full press release.

What is the date of the report for TNDM’s 8-K?

November 6, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 04:09 PM EST Learn about SEC filing dates

0001438133FALSE00014381332025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

FORM 8-K

____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

____________________________

Tandem Diabetes Care, Inc.

(Exact name of registrant as specified in its charter)

____________________________

Delaware

001-36189

20-4327508

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer  Identification No.)

12400 High Bluff Drive

92130

San Diego

California

(Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code: (858) 366-6900

N/A

(Former name or former address, if changed since last report)

____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class			Trading Symbol			Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share			TNDM			NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

____________________________

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, we issued a press release reporting our financial results for the quarter ended September 30, 2025. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

The information under this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)     Exhibits.

Number						Description
99.1						Press release of Tandem Diabetes Care, Inc. dated September 30, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.
By:						/s/ SHANNON M. HANSEN
						Shannon M. Hansen
						Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary

Date: November 6, 2025

3